PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2020 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Sat - Aug 22      Sun - Aug 23      Mon - Aug 24      Tue - Aug 25   

SUNDAY, AUGUST 23

8:15 - 10:00 AM
PLENARY SESSION
WELCOME/PLENARY SESSION 1
Chair/Organizer: Cathy Hayward, Anne Rose, and Robert Sidonio
Sheraton Ballroom


8:15

OPENING REMARKS
Peter Kouides. THSNA President


8:30

ANTICOAGULANT STEWARDSHIP IN THE ERA OF NOVEL THERAPEUTICS
Allison Burnett. University of New Mexico United States


9:00

BUILDING FROM BASIC BIOLOGY TO IMPROVE DIAGNOSIS AND CARE.
David Ginsburg.


9:30

ADAPTING TO NEW THERAPEUTIC OPTIONS: IMPLICATIONS FOR CLINICAL SERVICES AND COAGULATION LABORATORIES
Rajiv Pruthi. Mayo Clinic

9:45 - 10:30 AM
POSTER SESSION
POSTERS/EXHIBITS
Exhibit Hall - Riverwalk AB


A1. ANTICOAGULATION CLINICS


1

EVALUATION OF THE VALIDITY OF SAME-TT2R2 SCORE IN A COHORT OF VENOUS THROMBOEMBOLISM PATIENTS TREATED WITH WARFARIN IN QATAR
Eman Alhmoud1, Mohammed Abdulgelil2, Walid Mekkawi2, Osama Abd El Samad1, Hazem Elewa3, Abdelnasser Elzouki 2. 1Al-Wakra Hospital, Doha, Qatar. 2Hamad General Hospital, Doha, Qatar. 3Qatar University-College of Pharmacy, Doha, Qatar


2

THE RELATIONSHIP BETWEEN MISSED APPOINTMENTS AND ANTICOAGULATION OUTCOMES IN AN INNER CITY, SOCIOECONOMICALLY DISADVANTAGED POPULATION: A PROSPECTIVE COHORT STUDY
Ali Alobaidi1, Crissel Marie Arban1, Connie H. Yan1, Sandra Walko1, Miranda Kopfman1, Maryam Naveed1, Lisa K. Sharp1, 2, Edith Nutescu1, 2. 1Department of Pharmacy Systems, Outcomes, and Policy, University of Illinois at Chicago, Chicago, IL, USA. 2Center for Pharmacoepidemiology a Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA


3

COMPARING THE EFFECTIVENESS AND SAFETY OF RESTARTING WARFARIN USING LOADING DOSES VERSUS MAINTENANCE DOSES FOLLOWING AN ELECTIVE DAY PROCEDURE: A RETROSPECTIVE STUDY
Joey J. Champigny, Jeff Nagge, Caitlin Carter. University of Waterloo, Kitchener, ON, Canada


4

CREATION OF A NEONATAL THROMBOSIS CENTER AND ITS USE TO SUCCESSFULLY TREAT INFANTS WITH SEVERE THROMBOSES
Elizabeth Gunn3, Shailly Gaur3, Matthew Saxonhouse2, 3, Ashley Hinson1, 3. 1Division of Cancer and Blood Disorders, Charlotte, NC, USA. 2Division of Neonatology, Charlotte, NC, USA. 3Department of Pediatrics, Levine Children's Hospital, Charlotte, NC, USA


5

IMPLEMENTATION OF A PROCESS IMPROVEMENT INITIATIVE OPTIMIZES THE MANAGEMENT OF VENOUS THROMBOEMBOLISM IN THE OUTPATIENT SETTING OF A COMMUNITY HEALTH CENTRE.
Christie Kim, Connie Vo. St. Joseph Health Centre, Toronto, ON, Canada


6

EFFECT OF POLYPHARMACY ON TIME IN THERAPEUTIC RANGE OF WARFARIN THERAPY IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
Shaban Mohammed1, 4, Mohamed Kasem1, Amer Aljundi1, Mohammed Alhashemi2, Ayman El-Menyar3, 5, Osama Abd El Samad1, Moza Al Hail1, Nidal Asaad2. 1Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. 2Heart Hospital, Hamad Medical Corporation, Doha, Qatar. 32Department of Clinical Medicine, Weill Cornel Medical College, Doha, Qatar. 4American University of Barbados School of Medicine, Barbados, Barbados, Barbados. 53Department of Surgery, Clinical Research, Hamad Medical Corporation, Doha, Qatar


7

EVALUATION OF A POPULATION-BASED MANAGEMENT TOOL IN IDENTIFYING POTENTIAL INTERACTIONS BETWEEN DIRECT ORAL ANTICOAGULANTS AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AT A VETERANS AFFAIRS HEALTH CARE SYSTEM
Liem T. Nguyen, Rebecca F. Edwards, Jon E. Folstad, Juan D. Mobley, Jina W. Almond. Salisbury VA Health Care System, Salisbury, NC, USA


8

DRVV TESTING ON PATIENTS RECIEVING ANTICOAGULANT THERAPY
Maria Notini1, Dr. Thomas L Ortel2. 1Duke Health System, durham, NC, USA. 2Duke Health System, durham, NC, USA


9

A RETROSPECTIVE EVALUATION OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN OBESE END STAGE RENAL DISEASE (ESRD) PATIENTS
Tanvi Patil1, Abraham B Gebremariam2, Alamdeep Kaur1. 1Veterans health Administration, Salem, VA, USA. 2Applachian University school of Pharmacy, Oakwood, VA, USA


10

OPERATIONAL MODEL OF A PERIOPERATIVE ANTICOAGULATION AND BRIDGING CLINIC: A CASE STUDY
Laurie A. Sardo1, 2, Noah H. Spencer1, James Douketis1, 3, Joanne P. Cordell4, Julia Bayadinova1. 1St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada. 2Department of Nursing, McMaster University, Hamilton, ON, Canada. 3Department of Medicine, McMaster University, Hamilton, ON, Canada. 4Cordell Limited, Toronto, ON, Canada


11

COMPARABILITY OF POINT OF CARE VERSUS LABORATORY INR METHODS WITH VENOUS AND CAPILLARY SPECIMENS
Roona Sinha1, Nancy Hodgson2, Sibasis Daspal1, Matthew Bradshaw1, Lyon Martha1. 1University of Saskatchewan, Saskatoon, SK, Canada. 2Saskatchewan Health Authority, Saskatoon, SK, Canada


12

POINT-OF-CARE COAGULATION MONITORING USING A NOVEL OPTICAL SENSOR IN PATIENTS UNDERGOING CARDIAC SURGERY
Diane Malu Tshikudi1, 2, Alexandra G. Wirth1, 2, Michael N. Andrawes2, Seemantini K. Nadkarni1, 2, 3. 1Wellman Center for Photomedicine, Boston, MA, USA. 2Massachusetts General Hospital, Boston, MA, USA. 3Harvard Medical School, Boston, MA, USA


A2. PLATELET ACTIVATION AND BIOCHEMISTRY


13

UTILIZATION OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE PERIOPERATIVE MANAGEMENT OF INTRAVENOUS IMMUNOGLOBULIN, STEROIDS, AND BLOOD COMPONENT THERAPY IN A PATIENT WITH IDIOPATHIC THROMBOCYTOPENIA PURPURA REQUIRING EMERGENCY CORONARY ARTERY BYPASS GRAFTING.
Mark Walsh, MD1, Jordan Hatch, BS2, Hau C Kwaan, MD3, Faran Bokhari, MD, FACS4, Scott Thomas, MD5, Gina Arsenault, MT (ASCP), MSA5, Gerald Rinon, MT (ASCP)5, Robert March, MD1, Christopher Trumpower, CCP1, Rolan Pascual, MD6, Ashfaq Turk, MD1, Shareen Lee, MS1. 1St. Joseph Regional Medical Center, Mishawaka, IN, USA. 2Indiana University School of Medicine, South Bend, IN, USA. 3Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 4John H. Stroger, Jr. Hospital, Chicago, IL, USA. 5Beacon Health Systems, South Bend, IN, USA. 6Michiana Hematology and Oncology, Mishawaka, IN, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


14

IMPLEMENTING GOAL-HēM, A GOAL ATTAINMENT SCALING INSTRUMENT
Justin Stanley1, Taylor Dunn1, Jorge Caicedo2, Michael Denne2, Jonathan Roberts3, Kenneth Rockwood1, 4. 1DGI Clinical Inc, Halifax, NS, Canada. 2Baxalta US Inc, a Takeda company, Cambridge, MA, USA. 3Bleeding a Clotting Disorders Institute, Peoria, IL, USA. 4Dalhousie University, Halifax, NS, Canada


15

EFFICACY AND SAFETY RESULTS FROM A PHASE 3, RANDOMIZED, MULTICENTER STUDY OF RURIOCTOCOG ALFA PEGOL PHARMACOKINETIC-GUIDED PROPHYLAXIS TARGETING TWO FACTOR VIII TROUGH LEVELS IN PATIENTS WITH SEVERE HEMOPHILIA A (PROPEL STUDY): A CONSIDERATION FOR PERSONALIZED PROPHYLAXIS
Vlad C. Radulescu1, Robert Klamroth2, Jerzy Windyga3, Peter Collins4, Oleksandra Stasyshyn5, Hishamshah M. Ibrahim6, Werner Engl7, Srilatha D. Tangada8, Bruce Ewenstein8. 1University of Kentucky, Kentucky Children, Lexington, KY, USA. 2Vivantes Klinikum im Friedrichshain, Berlin Germany. 3Institute of Hematology and Transfusion Medicine, Warsaw, Poland. 4School of Medicine, Cardiff University, Cardiff, United Kingdom. 5Academy of Medical Sciences of Ukraine, Lviv, Ukrenia. 6Hospital Kuala Lumpur, Kuala Lumpur, Malaysia. 7Baxalta Innovations GmbH, a Takeda company, Vienna, Austria. 8Baxalta US Inc, a Takeda company, Cambridge, MA, USA


16

COMPARISON OF HEXAGONAL PHASE PHOSPHOLIPID NEUTRALIZATION ASSAYS FOR LUPUS ANTICOAGULANT DETECTION
Colin Douglas, Rachel Clarke, Navya Kesavan, Derek Lamont, Ali Sadeghi-Khomami, Amanda Wood, Karen Black. Precision BioLogic Inc, Dartmouth, NS, Canada


17

EXTERNAL QUALIFICATION OF THE WEB-ACCESSIBLE POPULATION PHARMACOKINETIC SERVICE - HEMOPHILIA (WAPPS-HEMO) MODELS FOR OCTOCOG ALFA (KOVALTRY) USING REAL PATIENT DATA
Pierre Chelle1, Dagmar Hajducek1, Mohammed Mahdi2, Stuart Young2, Alfonso Iorio3, Andrea Edginton1. 1School of Pharmacy, University of Waterloo, Waterloo, Canada. 2Bayer, Mississauga, Canada. 3McMaster-Bayer Endowed Research Chair for Clinical Epidemiology of Congenital Bleeding Disorders, Department of Medicine, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada


18

DERMATOGLYPHIC TRAIT ASYMMETRY: A PREDICTING TOOL FOR SCREENING HEMOPHILIC PATIENTS IN GUYANA.
Ameet K. Jha1, Daniel J. Kanhai1, Michael Chapp3, Sujatha D'costa2. 1Texila American University, East Bank Demerara, Guyana. 2American University of Antigua, St. Johns, Antigua & Barbuda. 3Georgetown Public Hospital Corporation, Georgetown, Guyana


19

HEMOSTASIOLOGICAL INDICATORS FOR DIAGNOSING PREECLAMPSIA IN PREGNANT WOMEN.
Bakhodir Kurbanov. Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan


20

RAPID DESENSITIZATION AND SUBSEQUENT IMMUNE TOLERANCE INDUCTION IN A PATIENT WITH HYPERSENSITIVITY AND INHIBITOR TO FACTOR VIII
William B Mitchell. Children's Hospital at Montefiore, Bronx, NY, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


21

PRELIMINARY VALIDATION OF A QUANTITATIVE HUMAN D-DIMER TEST ON A NOVEL HAND HELD LAB-ON-A-CHIP PLATFORM
Nahla M Heikal1, Melissa Stuart1, Wei Wang2, Shanghsuan Lin2, Xiyn Chen2, Robert McBane1, 3. 1Mayo Clinic. Laboratory Medicine and Pathology, Rochester, MN, USA. 2Zepto life technology, St. Paul, MN, USA. 3Mayo Clinic. Department of Medicine, Rochester, MN, USA


22

RISK OF THROMBOVASCULAR EVENTS IS INCREASED IN INDIVIDUALS WITH PREVALENT AUTOIMMUNE DISEASES: FINDINGS FROM A RAPID EVIDENCE REVIEW
Juliana Setyawan1, Nila Sathe2, Chris Rabbat1. 1Arena Pharmaceuticals, San Diego, CA, USA. 2Premier, Inc, Charlotte, NC, USA


23

CHARACTERISTICS EVALUATED FOR POTENTIAL ASSOCIATION WITH THROMBOVASCULAR EVENT RISK IN PATIENTS WITH PREVALENT AUTOIMMUNE CONDITIONS: FINDINGS FROM A RAPID EVIDENCE REVIEW
Nila Sathe1, Chris Rabbat2, Juliana Setyawan2. 1Premier, Inc, Charlotte, NC, USA. 2Arena Pharmaceuticals, San Diego, CA, USA

10:30 - 12:00 PM
HEMOSTASIS / BASIC SCIENCE
HEPARIN-INDUCED THROMBOCYTOPENIA
Chair/Organizer: Gow Arepally , Rebecca Kruse-Jarres
Sheraton Ballroom 1


10:30

NEW APPROACHES TO THE LABORATORY DIAGNOSIS OF HIT
Anand Padmanabhan. Versiti Wisconsin/Medical College of Wisconsin


11:00

ROLE OF THE ENDOTHELIUM IN HIT PATHOGENESIS
Lubica Rauova. The Children's Hospital of Philadelphia/University of Pennsylvania


11:30

SPONTANEOUS HIT: PATHOGENESIS AND CLINICAL FEATURES
Ted Warkentin. McMaster University

10:30 - 12:00 PM
HEMOSTASIS
NOT YOUR EVERYDAY BLEEDING
Chair/Organizer: Stephanie Cloutier, Stacy Croteau
Sheraton Ballroom 5


10:30

BLEEDING OF UNKNOWN CAUSE
Julie Jaffray.


11:00

NON HEMOSTATIC ROLE OF VON WILLEBRAND FACTOR
Paula James. Queen's University


11:30

BEYOND THE BLOOD VESSEL, CONNECTIVE TISSUE DISORDERS
Pamela Trapane.

10:30 - 12:00 PM
LABORATORY
UPDATES ON THE NEW GUIDELINES FOR THROMBOPHILIA TESTING
Chair/Organizer: Kristi Smock, Betsy Van Cott
Chicago Ballroom 10


10:30

GUIDELINES ON TESTING FOR ACTIVATED PROTEIN C RESISTANCE
Dot Adcock. Laboratory Corporation of America


11:00

GUIDELINES ON TESTING FOR PROTEIN C AND PROTEIN S
Richard Marlar. University of New Mexico


11:30

GUIDELINES ON TESTING FOR ANTITHROMBIN DEFICIENCY
Betsy Van Cott. Massachusetts General Hospital

12:15 - 1:45 PM
SATELLITE SYMPOSIUM
BAYER CORPORATE LUNCH SYMPOSIA
Chicago Ballroom 7


TAKEDA LUNCH SYMPOSIA: HEMOPHILIA A WITHOUT INHIBITORS: PERSONALIZING THERAPY WITH FACTOR VIII PROPHYLAXIS
Chicago Ballroom 6

2:00 - 3:30 PM
SHORT TALKS
BASIC SCIENCE OF HEMOSTASIS
Chicago Ballroom 6


ASSOCIATION BETWEEN DESIALYLATION AND APOPTOSIS AS A PREDICTOR OF PLATELET SURVIVAL IN MICE AND HEALTHY INDIVIDUALS.
Renata Grozovsky1, 2, Michael W Malloy1, 2, Elisabeth Battinelli1, 2. 1Hematology Division, Brigham and Women's Hospital, Boston, MA, USA. 2Harvard Medical School, Boston, MA, USA


EVALUATING THE ROLE OF SINGLE SITE GLYCAN MODIFICATION OF B-DOMAIN DELETED FACTOR VIII ON ANTI-FACTOR VIII EXPRESSION AND ANTIBODY BINDING
Jasmine C. Ito, John F. Healey, Hunter W. Baldwin, Ernest T. Parker, Shannon L. Meeks , Glaivy Batsuli. Aflac Cancer and Blood Disorders Center of Children, Atlanta, GA, USA


ANGIOGENIC ALTERATIONS IN VON WILLEBRAND DISEASE (VWD) AS A POSSIBLE CAUSE OF OCCULT BLEEDING IN THE STOMACH
Katharina Kaiser1, 2, Stefanie Lehner1, Hanna Allerkamp1, 2, Carsten Detering1, Mahnaz Ekhlasi-Hundrieser1, Christiane Pfarrer2, Mario von Depka1. 1Werlhof Institute, Hannover Germany. 2Institute of Anatomy, University of Veterinary Medicine, Hannover Germany


THE ROLE OF IGM REACTIVE TO THE C1 DOMAIN IN THE HUMORAL IMMUNE RESPONSE TO FACTOR VIII
Seema R Patel, Jasmine C Ito, Hunter W Baldwin, Courtney Cox, John Healey, Ernest Parker, Shannon L Meeks, Glaivy Batsuli. Aflac Cancer and Blood Disorders Center, Children, Atlanta, GA, USA


BLEEDING DISORDER IMPACT
Chicago Ballroom 7


LONG-TERM IMMUNOGENICITY, EFFICACY AND TOLERABILITY OF SIMOCTOCOG ALFA IN PATIENTS WITH SEVERE HAEMOPHILIA A WHO HAD COMPLETED THE NUPROTECT STUDY
Ellis J Neufeld1, Ri J Liesner2, on behalf of the GENA-15 Study Group1. 1St. Jude Children, Memphis, TN, USA. 2Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom


CHARACTERISTICS, COMPLICATIONS, AND SITES OF BLEEDING AMONG INFANTS AND TODDLERS LESS THAN 2 YEARS OF AGE WITH VWD: A REPORT FROM THE UNIVERSAL DATA COLLECTION SURVEILLANCE PROJECT.
Brandi Dupervil 1, Karon Abe1, Sarah O'Brien2, Meredith Oakley1, Roshni Kulkarni3, Vanessa Byams1, Mike Soucie1. 1Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2The Research Institute a Nationwide Children, Columbus, OH, USA. 3Centers for Bleeding and Clotting Disorders, Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USA


HEAVY MENSTRUAL BLEEDING IMPACT ON MENTAL HEALTH IN ADOLESCENT AND YOUNG ADULT WOMEN WITH BLEEDING DISORDERS
Mary McGrath1, Elisabeth Quint2, Angela Weyand1. 1Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA. 2Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA


SOCIALLY VULNERABLE YOUTH WITH BLEEDING DISORDERS: PILOTING NOVEL INTERVENTIONS IN CHILDREN'S HEALTHCARE (NICH)
David V Wagner, Michael Recht, Susan Lattimore, Kristina Haley, Erin Stang, Kim Spiro, Michael A Harris. Oregon Health and Science University, Portland, OR, USA


LABORATORY 1
Chicago Ballroom 9


COAGULATION AND CIRCULATING HEPARIN PROFILE IN PATIENTS WITH END-STAGE RENAL DISEASE UNDERGOING MAINTENANCE HEMODIALYSIS
Emily Bontekoe, Arjun Grewal, Jasdeep Bajwa, Nausheen Baig, Melissa Mazariegos, Vinod Bansal, Fakiha Siddiqui, Omer Iqbal, Debra Hoppensteadt, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


ASSESSMENT OF A NEW CHROMOGENIC FVIII ASSAY IN SEVERE HAEMOPHILIA A PLASMA CONTAINING EMICIZUMAB
Annette Bowyer, Steve Kitchen, Richard Wardle, Rhona Maclean. Sheffield Haemophilia and Thrombosis Centre, Sheffield, United Kingdom


THE UTILIZATION OF DOAC-STOP IN LABORATORY INVESTIGATION OF LUPUS ANTICOAGULANT FOR PATIENTS ON DIRECT ORAL ANTICOAGULANTS
Jing Jin1, Chris Pfaffroth1, Trang Vu1, Steven Baker2, James Zehnder2, 3. 1Department of Special Coagulation Clinical laboratory, Stanford Health Care, Palo Alto, CA, USA. 2Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA. 3Division of Hematology, School of Medicine, Stanford University, Stanford, CA, USA


THE INFLUENCE OF EMICIZUMAB (EMI) ON GLOBAL HEMOSTASIS IS BETTER MEASURED BY THROMBIN GENERATION ASSAY (TGA) THAN THROMBOELASTOGRAPHY
Erika J Martin1, Gita V Massey2, Janice G Kuhn1. 1Virginia Commonwealth University, Richmond, VA, USA. 2Children, Richmond, VA, USA


THROMBOSIS: CLINICAL
Chicago Ballroom 10


DEVELOPMENT OF A BRIEF SCREENING TOOL FOR EMOTIONAL HARM ASSOCIATED WITH VENOUS THROMBOEMBOLISM
Keith S. Keddington1, Aubrey E. Jones1, Michael Feehan2, Daniel M. Witt1. 1University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, USA. 2Kantar LLC, Boston, MA, USA


VENOUS THROMBOEMBOLISM IN PATIENTS WITH UTERINE FIBROIDS
Hira Latif1, Valentina Baez Sosa1, Stephen J. Fernandez2, Nicholas D. Hazen1, James K. Robinson1, Vadim Morozov1, Kelly W. Fitzpatrick1. 1MedStar Washington Hospital Center, Washington, DC, USA. 2MedStar Health Research Institute, Washington, DC, USA


RACIAL DISPARITIES ACROSS AGE GROUPS IN ILLINOIS HOSPITAL ADMISSIONS FOR PULMONARY EMBOLISM
Karlyn Martin1, Megan McCabe2, Joseph Feinglass3, Sadiya Khan2. 1Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA


CHOICE OF ANTICOAGULATION THERAPY AND PERSISTENCE AMONG PATIENTS WITH ATRIAL FIBRILLATION FOLLOWING A SHARED DECISION-MAKING ENCOUNTER
Jeff Nagge1, Sherilyn Houle1, Eunice Chan1, Kristen Stypa1, Ai-Leng Foong1, Ryan McKee2. 1University of Waterloo, Kitchener, ON, Canada. 2Centre for Family Medicine, Kitchener, ON, Canada

3:30 - 4:15 PM
POSTER SESSION
POSTERS/EXHIBITS
Exhibit Hall - Riverwalk AB


A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION


24

COLLAGEN TURNOVER MARKERS IN HEMOPHILIA
Hira Latif1, Syed W Haider1, Craig M Kessler2. 1MedStar Washington Hospital Center, Washington, DC, USA. 2MedStar Georgetown University Hospital, Washington, DC, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


25

REACTIVE THROMBOCYTOSIS IN PEDIATRIC POPULATION: ANALYSIS OF INDOOR PATIENTS IN A TERTIARY CARE HOSPITAL
Asma N Cheema1, Zulfiqar A Rana2, Zille Rubab1. 1Department of Pathology, Children's Hospital a The Institute of Child Health, Multan, Pakistan. 2Department of Hematology a Oncology, Children's Hospital a The Institute of Child Health, Multan, Pakistan


26

SUCCESSFUL PERIPARTUM MANAGEMENT IN BERNARD SOULIER SYNDROME WITH SEVERE THROMBOCYTOPENIA AND A PREVIOUSLY UNREPORTED GP1BA PATHOLOGIC VARIANT.
Colleen Ciccosanti1, Claire Philipp2. 1Rutgers Robert Wood Johnson Medical School, Department of Medicine, New Brunswick, NJ, USA. 2Rutgers Robert Wood Johnson Medical School, Department of Hematology, New Brunswick, NJ, USA


27

HEPATIC DISORDERS CONTRIBUTE TO PLATELET DYSFUNCTION
Ambar Farooqui, Cassandra Bacher, Fakiha Siddiqui, Bharathi Darvath, Debra Hoppensteadt, Omer Iqbal, Jawed Fareed, Magdalena George, David VanThiel. Loyola University Medical Center, Maywood, IL, USA


28

EVALUATION OF ANTICOAGULATION PRESCRIBING PATTERNS IN PATIENTS WITH SUSPECTED OR CONFIRMED HEPARIN-INDUCED THROMBOCYTOPENIA
Jona Lekura, Ashley Semma, Mya Tran, Ahlam Almansoub, Klarita Seitllari, Philip Kuriakose. Henry Ford Health System, Detroit, MI, USA


29

ANALYSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) TESTING AND IMPLEMENTATION OF ELECTRONIC RECORD BASED CALCULATION OF 4T SCORE
Hannah L McRae1, Rialnat Lawal2, Mofiyin Obadina2, Frank Akwaa3, Majed Refaai1, 3. 1Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. 2Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA. 3Department of Medicine, Division of Hematology/Oncology, Rochester, NY, USA


30

CLINICAL APPLICATION OF THE 4TS SCORE AND PLATELET COUNT TRENDS IN PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION WITH HEPARIN-INDUCED THROMBOCYTOPENIA - A SINGLE INSTITUTION STUDY
Anil K. Rengan1, Daniel Stapor1, Mark Weiner1, Hauqing Zhao1, Nadia Ali2. 1Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. 2Department of Hematology at Temple University Hospital, Philadelphia, PA, USA


31

COMPARISON OF TWO DIFFERENT ELISA METHODS FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) SCREENING ON AN AUTOMATED ELISA PLATFORM
Paul W Riley, John G Chromczak. Diagnostica Stago, Inc, Parsippany, NJ, USA


32

WHOLE BLOOD IMPENDENCE AGGREGOMETRY AS A SCREEN FOR PLATELET DENSE GRANULE DEFICIENCY
Marian A. Rollins-Raval, Jay S. Raval, Richard A. Marlar. University of New Mexico, Albuquerque, NM, USA


33

PLATELET REFRACTORINESS AND THE ROLE OF LEUCODEPLETION BEFORE BONE MARROW TRANSPLANTATION IN SICKLE CELL DISEASE PATIENTS
Ambreen Sheikh. Dow University, Karachi Pakistan


34

LASER SPECKLE AGGREGOMETRY: A NOVEL TECHNIQUE FOR MONITORING PLATELETS FUNCTION
Diane M. Tshikudi1, 2, Asael Papour1, 2, Xin Liang1, 2, John Barranco1, Michael N. Andrawes1, Seemantini K. Nadkarni1, 2, 3. 1Wellman Center for Photomedicine, Boston, MA, USA. 2Massachusetts General Hospital, Boston, MA, USA. 3Harvard Medical School, Boston, MA, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


35

RISK FACTORS AMONG OUTPATIENTS AND HOSPITALIZED PATIENTS WITH VTE USING POPULATION-BASED SURVEILLANCE DATA FROM TWO US COUNTIES 2012-2014
Karon Abe1, Alys Adamski1, Aaron Wendleboe2, Nimia Reyes1, Gary Raskob2, Thomas Ortel3. 1Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2Hudson College of Public Health, University of Oklahoma Health Sciences, Norman, OK, USA. 3Division of Hematology, Duke University Medical Center Durham, NC, USA


36

VENOUS THROMBOEMBOLISM IN MELANOMA PATIENTS: ANALYSIS FROM THE NATIONAL INPATIENT SAMPLE DATABASE
Hussam Alhasson1, Anas Saad 2, Yu Zhao1, Zimu Gong 3, Muneer Alhusseini4. 1Rochester Regional Health/ Unity Hospital, Rochester, NY, USA. 2Cleveland Clinic Foundation, Cleveland, OH, USA. 3AMITA Health St Joseph Hospital, Chicago, IL, USA. 4Ascension St John Hospital, Detroit, MI, USA


37

VALIDATION OF CHROMOGENIC FACTOR VIII ACTIVITY ASSAYS AT CHILDREN'S HOSPITAL LOS ANGELES (CHLA)
Joshua M. Brown, PhD1, Melissa Arevalo1, Desiree Tan-Castillo1, Edward Leung, PhD, DABCC, FAACC1, 2, Guy Young, MD1, 2, Maurice O'Gorman, MBA, MSc, PhD, D(ABMLI)1, 2. 1Children's Hospital Los Angeles, Los Angeles, CA, USA. 2University of Southern California Keck School of Medicine, Los Angeles, CA, USA


38

EFFICACY OF UPFRONT LOW DOSE COMBINED IMMUNOSUPPRESSION IN ACQUIRED HEMOPHILIA A: A SINGLE CENTER RETROSPECTIVE COHORT STUDY
Lorraine A. Cafuir, Duc Q. Tran, Anthony DeBalsi, Christine L. Kempton. Emory University, Atlanta, GA, USA


39

SURGICAL SPLENECTOMY AND RISK OF VENOUS THROMBOEMBOLISM IN SICKLE CELL DISEASE
Jennifer Chen1, Manuela Plazas Montana2, Elizabeth Williams2, Payal Desai3, Joshua Field4, Sophie Lanzkron2, Jane Little5, Deepa Manwani6, Lynne Neumayer7, Rakhi P. Naik 2. 1The Johns Hopkins School of Medicine, Baltimore, MD, USA. 2Department of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 3The Ohio State University, Columbus, OH, USA. 4Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 5Department of Hematology and Oncology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. 6Department of Pediatrics, Albert Einstein College of Medicine, New York City, NY, USA. 7Department of Hematology Oncology, UCSF Benioff Children's Hospital and Research Center Oakland, Oakland, CA, USA


40

ASSESSMENT OF JOINT HEALTH USING POINT-OF-CARE ULTRASOUND IN WOMEN WITH BLEEDING DISORDERS
Kelli A Fraga, Rachel S Leeman, Joanna A Davis, Fernando F Corrales-Medina. University of Miami - Hemophilia Treatment Center, Miami, FL, USA


41

THROMBOSIS AND TRANSIENT ACQUIRED THROMBOPHILIA TRIGGERED BY EPSTEIN-BARR VIRUS IN PEDIATRICS
Jessica Garcia1, 2, Ayesha Zia1, 2. 1University of Texas Southwestern, Dallas, TX, USA. 2Children's Medical Center, Dallas, TX, USA


42

DIGITAL MONITORING OF SERIOUS ADVERSE EVENTS SIGNALS IN PATIENTS WITH BLEEDING DISORDERS
Marc Lara1, Michael Callaghan2, Meera Chitlur2, Suchitra Acharya3, Joseph Stanco3, Guy Young4, Robert Sidonio5, Maissaa Janbain6, Amina Rafique6, Angela Kellum6, Cindy Leissinger6. 1MicroHealt, Inc, NY, NY, USA. 2Children's Hospital of Michigan, Detroit, MI, USA. 3Northwell Health, New Hydde Park, NY, USA. 4Children's Hospital of Los Angeles, Los Angeles, CA, USA. 5Children's Healthcare of Atlanta, Atlanta, GA, USA. 6Tulane University School of Medicine, New Orleans, LA, USA


43

BLEEDING PREDICTIONS FOR PATIENTS WITH HEMOPHILIA A USING MACHINE LEARNING.
Marc Lara1, Marcela Barrios2, Angela Kellum3, Jonathan Elliott2, Milena Almagro2. 1MicroHealth, Inc, New York, NY, USA. 2New York University. Department of Economics, New York, NY, USA. 3Tulane University School of Medicine, New Orleans, LA, USA


44

DETERMINING PATHOGENICITY OF NOVEL VARIANTS FOUND IN BLEEDING/CLOTTING/PLATELET DISORDERS
Jihyun Moon, Jooeun Lim, Gayatri Raghuraman, Violet Votin, Bjorn Stromsness, James Kain, Mike Ero. Machaon Diagnostics, Inc, Oakland, CA, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


45

THE CONTRIBUTION OF CELL POPULATION DATA (CPD) COMPARED TO THE CONCENTRATION OF C-REACTIVE PROTEIN IN HOSPITALIZED PATIENTS IN SURGICAL RESUSCITATION IN UNIVERSITY HOSPITAL IBN ROCHD OF CASABLANCA-MOROCCO
Anass JARMOUMI1, Salma HASNANE1, Hanaa BENCHAREF1, Houcine BARROU2, Bouchra OUKKACHE1. 1Hematology laboratory of University Hospital Ibn Rochd, Casablanca, Morocco. 2Surgical resuscitation in University Hospital Ibn Rochd, Casablanca, Morocco


46

CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF WILATE DURING PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH VON WILLEBRAND DISEASE (VWD)
Bruce A Schwartz1, Robert Sidonio2. 1Octapharma, Hoboken, NJ, USA. 22Hemophilia of Georgia Center for Bleeding a Clotting Disorders, Atlanta, GA, USA

4:15 - 5:45 PM
HEMOSTASIS / LABORATORY
EVALUATING FOR VON WILLEBRAND DISEASE
Chair/Organizer: Bethany Samuelson Bannow, William Nichols
Sheraton Ballroom 5


4:15

DIAGNOSTIC TESTING FOR VON WILLEBRAND DISEASE: TRENDS AND INSIGHTS FROM EXTERNAL QUALITY ASSESSMENTS OF NORTH AMERICAN LABORATORY PRACTICES
Jameel Abdulrehman. University Health Network


4:45

ASSESSMENT OF CHILDREN FOR VON WILLEBRAND DISEASE: NEW EVIDENCE ON HOW MANY TIMES WE NEED TO TEST
Bhavya Doshi. Children's Hospital of Philadelphia


5:15

GENETIC TESTING FOR VON WILLEBRAND DISEASE. UPDATE ON WHEN IT IS USEFUL
Veronica Flood. Medical College of Wisconsin

4:15 - 5:45 PM
BASIC SCIENCE
NEW INSIGHTS ON COAGULATION
Chair/Organizer: Kenneth Mann, Muriel Maurer
Chicago Ballroom 10


4:15

NEW INSIGHTS ON FACTOR XIII AND THROMBOSIS
Muriel Maurer. University of Louisville


4:45

ANTI-INFLAMMATORY EFFECTS OF FVIIA
LVM Rao. The University of Texas Health Science Center at Tyler


5:15

INITIATION OF BLOOD COAGULATION
James Morrisey. University of Michigan Medical School

4:15 - 5:45 PM
THROMBOSIS
THE CHANGING LANDSCAPE OF CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM
Chair/Organizer: James Douketis , Crystal Watson
Sheraton Ballroom 1


4:15

PRIMARY VTE PROPHYLAXIS IN CANCER PATIENTS
Marc Carrier. Ottawa Hospital Research Institute


4:45

TREATMENT OF CANCER-ASSOCIATED VTE, INCLUDING SPECIAL AND DIFFICULT PATIENT POPULATIONS.
Michael Streiff. Johns Hopkins University School of Medicine


5:15

CLINICAL CONTROVERSIES IN TREATING THROMBOSIS
Sam Schulman. McMaster University

5:45 - 6:30 PM
POSTER SESSION
OPENING RECEPTION/POSTERS/EXHIBITS
Exhibit Hall - Riverwalk AB


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


47

RECOGNIZING REASONS OF UNWARRANTED COAGULATION TESTING IN MEDICALLY ILL PATIENTS - A SNEAK PEEK
Sidra Asad Ali, Amir Khan, Naila Noor. Patel Hospital, Karachi, Pakistan


48

LEVERAGING TURBIDIMETRY AND THROMBOELASTOGRAPHY TO CHARACTERIZE FIBRIN FORMATION UNDER DIVERSE CLOTTING CONDITIONS
Ziqian Zeng1, 2, Mahussi Fagnon1, Tanmaye Nallan Chakravarthula1, 2, Nathan / J Alves1, 2. 1Indiana University School of Medicine: Emergency Medicine, Indianapolis, IN, USA. 2Purdue University: Weldon School of Biomedical Engineering, West Lafayette, IN, USA


49

IDENTIFY THE KNOWLEDGE, ATTITUDE AND PRACTICE OF HEALTHCARE PROVIDERS TOWARD PRESCRIBING FACTOR REPLACEMENT AT FEDERALLY FUNDED HEMOPHILIA TREATMENT CENTERS IN THE UNITED STATES.
Maya Bloomberg1, Krysten Sargenton1, Karina Gattamorta2, Debbie Anglade2. 1University of Miami Hemophilia Treatment Center, Miami, FL, USA. 2University of Miami School of Nursing a Health Studies, Miami, FL, USA


50

PROFILE OF INFLAMMATORY BIOMARKERS AND COAGULATION FACTORS IN END-STAGE RENAL DISEASE
Emily Bontekoe, Arjun Grewal, Vinod Bansal, Debra Hoppensteadt, Melissa Mazariegos, Jawed Fareed. Loyola University Chicago, Maywood, IL, USA


51

COAGULATION PROFILE DERANGEMENT AND DISEASE SEVERITY/SPECTRUM IN PEDIATRIC POPULATION
Asma N Cheema1, Syeda Saima Irshad2, Muhammad Aamer Sujjad1, Muhammad Gulsher1. 1Department of Pathology, Children's Hospital a The Institute of Child Health, Multan, Pakistan. 2Department of Pediatric medicine Children's Hospital a The Institute of Child Health, Multan, Pakistan


52

PERFORMANCE CHARACTERISTICS OF A CHROMOGENIC FACTOR VIII METHOD ON THE STA-R EVOLUTION XP
Ronda A Crist1, Daniel A Stephens1, George M Rodgers1, 2, 3, Jessica Corean1, 2, Karen A Moser1, 2, Kristi J Smock1, 2. 1ARUP Institute for Clinical and Experimental Pathologyr, Salt Lake City, UT, USA. 2Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA. 3Division of Hematology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA


53

THE DEVELOPMENT AND IMPACT OF A HEMOSTATIC STEWARDSHIP PROGRAM AT TWO LARGE ACADEMIC MEDICAL CENTERS
Kathryn Dane, John Lindsley, Satish Shanbhag, Michael Streiff. The Johns Hopkins Hospital, Baltmore, MD, USA


54

ASSOCIATION OF HYPERCOAGULABLE STATE WITH CLINICAL SEVERITY OF SICKLE CELL DISEASE IN SUDANESE PATIENTS
Alaaeddin M. Elzubeir1, 2, Shima H. Elsheikh2, Tayseer A. Alabid2. 1University of Colorado Denver, Aurora, CO, USA. 2University of Khartoum, Khartoum, Sudan


55

EVALUATION OF A RAPID AUTOMATED CHEMILUMINESCENT ADAMTS13 ACTIVITY ASSAY FOR THE ACL ACUSTAR
R Fretwell, T Pitchford, SM Cooper, S Kitchen. Sheffield Teaching Hospitals, Sheffield, United Kingdom


56

EFFECTS OF TAI CHI ON BALANCE IN INDIVIDUALS LIVING WITH HEMOPHILIA
Mark Krimmel1, Rebecca Kruse-Jarres2, Bruno Steiner3. 1Washington Center for Bleeding Disorders, Seattle, WA, USA. 2University of Washington, Seattle, WA, USA. 3Washington Center for Bleeding Disorders, Seattle, WA, USA


57

EFFECT OF HUMAN PLASMA ON EVALUATION OF COAGULATION FACTOR VIII PRODUCT PURITY BY WESTERN BLOT
Yideng Liang, Mohammad B Uddin, Alexey V Khrenov, Sergey S Akimov, Timothy K Lee, Mikhail V Ovanesov. U. S. Food and Drug Administration, Silver Spring, MD, USA


58

KNOCKDOWN OF HEPATIC TAFI OR A2AP BY GALNAC-SIRNA STRATEGY EXPEDITED THROMBOLYSIS IN A RODENT LARGE-VEIN ELECTROLYTIC INJURY MODEL
Jingxuan Liu1, Brian Cooley2, Akin Akinc1, Anna Borodovsky1, Patrick Haslett1. 1Alnylam Pharmaceuticals, Cambridge, MA, USA. 2University of North Carolina, Chapel Hill, NC, USA


59

INFLUENCE OF DOAC REMOVE ON COAGULATION ASSAYS IN SAMPLES FROM PATIENTS ON ANTICOAGULATION
Zahra Al-Qawzai1, Nada Yartey2, Chris Dale2, Minal Dave2, Sean Platton2. 1Clinical Biochemistry Laboratory, Royal London Hospital, London, United Kingdom. 2Haemostasis Laboratory, Royal London Hospital, London, United Kingdom


60

CRYOCHECK™ CHROMOGENIC FACTOR VIII: A NEW KIT FOR THE DETERMINATION OF FACTOR VIII:C ACTIVITY
Tara Quinton, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc, Dartmouth, NS, Canada


61

PERFORMANCE OF CRYOCHECK™ CHROMOGENIC FACTOR VIII IN THE RECOVERY OF FACTOR VIII REPLACEMENT THERAPIES
Tara Quinton, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc, Dartmouth, NS, Canada


62

DEVELOPMENT AND PERFORMANCE CHARACTERIZATION OF AN AUTOMATED CHROMOGENIC ASSAY FOR HUMAN FACTOR IX ACTIVITY
Narayanan Ramamurthy, Sean Duffin, Cheryl Kucharshi, Zach Vandertuin, Michael Morris. r2 Diagnostics Inc, Suoth Bend, IN, USA


63

MATHEMATICAL MODELING OF IMPACTS OF VARIABLE HEMATOCRIT AND BLOOD COLLECTION FILL VOLUME ON CITRATED PLASMA FOR COAGULATION TESTING
Jay S. Raval, Marian A. Rollins-Raval, Richard A. Marlar. University of New Mexico, Albuquerque, NM, USA


64

EFFICACY AND SAFETY OF N8-GP FOR PROPHYLAXIS AND BLEED CONTROL IN US VS GLOBAL PATIENTS WITH HEMOPHILIA A: RESULTS FROM THE PATHFINDER CLINICAL PROGRAM
Allison P. Wheeler1, Miguel Escobar2, Susan Kearney3, Leslie Raffini4, Janice M. Staber5, Suchitra Acharya6, David L. Cooper7, Steven Lentz8. 1Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA. 2University of Texas Health Science Center, Houston, TX, USA. 3Children, Minneapolis, MN, USA. 4Children, Philadelphia, PA, USA. 5University of Iowa Stead Family Children, Iowa City, IA, USA. 6Cohen Children, New Hyde Park, NY, USA. 7Novo Nordisk Inc, Plainsboro, NJ, USA. 8University of Iowa, Iowa City, IA, USA


65

PHARMACOVIGILANCE OF VON WILLEBRAND FACTOR/COAGULATION FVIII COMPLEX (HUMAN)- 10 YEARS' EXPERIENCE
Claudio Sandoval, Azim Saifee, Dipen Patel, Huub Kreuwel. Octapharma USA, Hoboken, NJ, USA


66

VON WILLEBRAND DISEASE IN PREGNANCY AND THE USE OF EPIDURAL ANALGESIA
Maissaa Janbain, MD, Radia Ksayer, MD, Anna Swigert, BS. Tulane University School of Medicine, New Orleans, LA, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


67

A ROLE FOR NURSES: HOSPITAL-WIDE ROLL OUT OF EXTREMITY PRECAUTIONS FOR NEW FINDING OF EXTREMITY THROMBOSIS PROCEDURE AT A PEDIATRIC TERTIARY CARE SETTING - A QUALITY IMPROVEMENT INITIATIVE
Marilyn Blumenstein, Emily Roberto. The Children's Hospital of Philadelphia, Philadelphia, PA, USA


68

PHARMACOKINETICS OF RECOMBINANT VON WILLEBRAND FACTOR IN PERIPARTUM MANAGEMENT OF AN ADOLESCENT WITH TYPE 2M VON WILLEBRAND DISEASE
Caitlin Montcrieff1, 2. 1Rhode Island Hemostasis a Thrombosis Center, Providence, RI, USA. 2Hasbro Children's Hospital, Providence, RI, USA


69

RETROSPECTIVE ANALYSIS OF TEN YEARS OF PT AND APTT VALIDATION DATA IN A REFERENCE LAB
Dan A Stephens, Ronda A Crist, George M Rogers, Kristi J Smock, Karen Moser. ARUP Institute for Clinical and Experimental Pathologyr, Salt Lake City, UT, USA

6:30 - 8:30 PM
SATELLITE SYMPOSIUM
ALNYLAM CORPORATE DINNER SYMPOSIA
Chicago Ballroom 7


PFIZER DINNER SYMPOSIA: PERSPECTIVES ON HEMOPHILIA B CARE IN AN ERA OF ADVANCED THERAPEUTICS AND EXTRAVASCULAR FIX SCIENCE: PAST, PRESENT AND FUTURE CONSIDERATIONS
Chicago Ballroom 6